BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, April 20, 2026
Home » Authors » Cormac Sheridan

Articles by Cormac Sheridan

IsoTis Getting Foothold In U.S. Through Acquisition Of GenSci

June 4, 2003
By Cormac Sheridan
IsoTis SA unveiled a definitive merger agreement Tuesday to acquire GenSci Regeneration Sciences Inc., a Toronto-based orthobiologics firm emerging from Chapter 11 bankruptcy.(BioWorld International)
Read More

IsoTis Getting Foothold In U.S. Through Acquisition Of GenSci

June 4, 2003
By Cormac Sheridan
IsoTis SA unveiled a definitive merger agreement Tuesday to acquire GenSci Regeneration Sciences Inc., a Toronto-based orthobiologics firm emerging from Chapter 11 bankruptcy.(BioWorld International)
Read More

BioXell Closes Second Round Early, Raises EUR17M For Pipeline

May 28, 2003
By Cormac Sheridan

Medivir, GSK Agree To EUR86M Deal For Phase I HIV Candidate

May 28, 2003
By Cormac Sheridan

Medivir, GSK Agree To EUR86M Deal For Phase I HIV Candidate

May 28, 2003
By Cormac Sheridan
Medivir AB entered its largest drug development deal to date, a pact worth up to €86 million with GlaxoSmithKline plc to develop its HIV drug MIV-210. The news sent the Huddinge, Sweden-based company's share price soaring by almost 50 percent during trading on the Stockholm Stock Exchange last week, to close at SEK61 Friday. (BioWorld International)
Read More

Sidec Raises SEK10M For Protein Visualization, Eyes Breaking Even

May 28, 2003
By Cormac Sheridan

Medivir, GSK Agree To EUR86M Deal For Phase I HIV Candidate

May 28, 2003
By Cormac Sheridan

BioXell Closes Second Round Early, Raises EUR17M For Pipeline

May 28, 2003
By Cormac Sheridan

Sidec Raises SEK10M For Protein Visualization, Eyes Breaking Even

May 28, 2003
By Cormac Sheridan

Medivir, GSK Agree To EUR86M Deal For Phase I HIV Candidate

May 28, 2003
By Cormac Sheridan
Medivir AB entered its largest drug development deal to date, a pact worth up to €86 million with GlaxoSmithKline plc to develop its HIV drug MIV-210. The news sent the Huddinge, Sweden-based company's share price soaring by almost 50 percent during trading on the Stockholm Stock Exchange last week, to close at SEK61 Friday. (BioWorld International)
Read More
Previous 1 2 … 307 308 309 310 311 312 313 314 315 … 335 336 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 20, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • Novel caspase-2 inhibitor shows in vivo neuroprotective effects

    BioWorld Science
    Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing